Disappointment For Novartis As England’s NICE Says No To Migraine Drug Again
Doubts linger over Aimovig's cost effectiveness
Executive Summary
New cost-effectiveness analyses and an improved deal for Aimovig have failed to change the health technology assessment body's mind about routine funding for the migraine prevention drug.
You may also be interested in...
UK Funding Nod For Novartis Migraine Drug After Bumpy Ride
Following two previous rejections by the UK’s health technology assessment body and an appeal, Aimovig is now available on the National Health Service for preventing migraine.
Scottish HTA Body OKs Novartis’ Aimovig For Migraine And Eisai’s Lenvima For Cancer
Scotland’s health technology appraisal body has OKd Novartis’s Aimovig for migraines. England’s NICE has postponed a meeting on the drug after a large number of comments were received following the institute’s initial knockback.
EMA Probe Finds No Link Between GLP-1s And Suicidal Thoughts & Actions
After reviewing the evidence from non-clinical studies, clinical trials, post-marketing surveillance data and other studies, the European Medicines Agency said there was no need to update the product information for 11 diabetes and weight management drugs.